Biogen Secures $850M China Rights to Felzartamab, First Local Anti-CD38 MM Therapy
Biogen will acquire exclusive Greater China rights to TJ Biopharma’s anti-CD38 immunotherapy felzartamab for up to $850 million, including the submitted NMPA BLA for relapsed/refractory multiple myeloma. Manufacturing remains at TJ’s Hangzhou GMP facility, making felzartamab China’s first domestically produced anti-CD38 therapy.
1. Deal Details
On 20 April 2026, Biogen agreed to pay up to $850 million for exclusive development and commercialization rights to TJ Biopharma’s felzartamab in Greater China, securing the submitted NMPA BLA for relapsed/refractory multiple myeloma and retaining responsibility for commercial launch.
2. Manufacturing and Competitive Landscape
Manufacturing will remain at TJ Biopharma’s Hangzhou GMP facility, positioning felzartamab as China’s first domestically produced anti-CD38 immunotherapy with a 1.5-hour infusion versus Darzalex’s seven-hour regimen. Janssen’s subcutaneous Darzalex Faspro is currently trialled in China with a 3–5 minute administration time and potential home-use approval.
3. China Market Potential
With anti-CD38 therapies representing a $7.6 billion global market in 2025 and Darzalex holding 87.5% share, market forecasts project felzartamab capturing 14.6% of China’s $458 million multiple myeloma market by 2029 under government incentives for local production.